The IRIS-HIV assay, a point-of-care, multiplex serological assay to identify HIV Infection and Vaccine-Induced Seropositivity

开发诊断方法以区分HIV感染和疫苗诱导的血清阳性：几年的临床试验表明，一些HIV疫苗可以引起持久（>15年）的血清学免疫应答，这在常见的诊断测试中可能与HIV感染混淆。这种现象被称为疫苗诱导的血清反应性或血清阳性（VISR/VISP）。该计划的总体目标是支持开发新的血清学和核酸检测方法，这些方法可以识别HIV感染，同时避免VISP导致的假阳性结果，具有高灵敏度和特异性。

Development of Diagnostics to Differentiate HIV Infection from Vaccine Induced Seropositivity: Several years of clinical trials have revealed that some HIV vaccines can elicit long-lasting (>15 years) serological immune responses that can be confused with HIV infection in common diagnostic tests. This phenomenon is known as vaccine-induced sero-reactivity or sero-positivity (VISR/VISP). The overarching goal of this program is to support the development of new serological and nucleic acid assays that can identify HIV infection while avoiding false-positive results due to VISP, with high sensitivity and specificity.